Sionna Therapeutics (SION) CLO sells 10,250 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sionna Therapeutics, Inc. Chief Legal Officer Jennifer Fitzpatrick reported an exercise-and-sell transaction involving company common stock. She exercised options to acquire 10,250 shares of common stock at an exercise price of $6.11 per share and sold the same 10,250 shares in an open-market transaction at a weighted-average price of $43.5963 per share. The filing states that this sale was automatically executed under a Rule 10b5-1 trading plan adopted on June 5, 2025. Following these transactions, the report shows she holds no shares of common stock directly. The underlying option grant vested 25% on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,250 shares ($446,862)
Net Sell
3 txns
Insider
Fitzpatrick Jennifer
Role
Chief Legal Officer
Sold
10,250 shs ($447K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,250 | $0.00 | -- |
| Exercise | Common Stock | 10,250 | $6.11 | $63K |
| Sale | Common Stock | 10,250 | $43.5963 | $447K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 40,685 shares (Direct, null);
Common Stock — 10,250 shares (Direct, null)
Footnotes (1)
- This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.89 to $44.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. 25% of the shares underlying this option vested on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 10,250 shares
Sale price (weighted average): $43.5963 per share
Shares acquired via exercise: 10,250 shares
+3 more
6 metrics
Shares sold
10,250 shares
Common Stock sold in open-market transaction
Sale price (weighted average)
$43.5963 per share
Open-market sale on July 6, 2026
Shares acquired via exercise
10,250 shares
Common Stock received from option exercise
Option exercise price
$6.11 per share
Non-Qualified Stock Option conversion price
Common shares after transaction
0 shares
Directly held Sionna common stock following transactions
Option vesting schedule
25% on June 3, 2025; remainder over 36 months
Vesting conditioned on continued service
Key Terms
Rule 10b5-1 trading plan, weighted average price, Non-Qualified Stock Option, vesting
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
vesting financial
"25% of the shares underlying this option vested on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did Sionna Therapeutics (SION) report for its Chief Legal Officer?
Sionna Therapeutics reported that its Chief Legal Officer, Jennifer Fitzpatrick, exercised options for 10,250 shares and sold all 10,250 shares in the open market. The sale was reported as a routine exercise-and-sell transaction in the Form 4 filing.
Was the Sionna Therapeutics (SION) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the transaction was automatically executed under a Rule 10b5-1 trading plan adopted on June 5, 2025. Such plans pre-schedule trades, indicating the timing of the sale was set in advance rather than decided opportunistically.
What are the vesting terms of the Sionna Therapeutics stock options exercised in this filing?
The footnotes state that 25% of the option grant vested on June 3, 2025, with the remaining 75% vesting in thirty-six equal monthly installments. Continued service is required on each vesting date for additional installments to vest.
What type of derivative security was involved in the SION insider’s transaction?
The transaction involved a Non-Qualified Stock Option with a right to buy 10,250 shares of Sionna common stock at $6.11 per share. These options were exercised and converted into shares, which were then sold in the open market.